NN1213 - 一种强效,长效和选择性的人类氨基林类似物
Kirsten Dahl1, Kirsten Raun1, Jakob Lerche Hansen1
1Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark.
Journal of medicinal chemistry
|July 3, 2024
概括
一种新型的氨酸类比物NN1213有效抑制食欲并降低体重,主要是通过脂肪质量减轻. 这种长效化合物在临床环境中显示出对体重管理的前景.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 肥胖问题研究研究
背景情况:
- 氨酸是一种酸家族的,通过后脑和下丘脑的受体调节食欲.
- 原生氨基酸受体配体的生物半衰期很短.
- 脂肪酸结合增强了的半衰期和治疗潜力.
研究的目的:
- 开发和表征NN1213,一种长效的人类氨基林类似物.
- 评估NN1213在抑制食欲和减轻体重方面的疗效.
- 在临床前模型中评估NN1213的药理动力学和药理动力学特性.
主要方法:
- 结构-活性关系研究,以优化NN1213的特性 (溶解性,稳定性,亲和性,选择性).
- 在老鼠和狗体内研究以评估食欲抑制和作用持续时间.
- 使用MRI对肥胖大鼠进行剂量研究,以评估体重减轻和身体组成的变化.
主要成果:
- 在老鼠和狗中,NN1213证明了剂量依赖的食欲抑制与长时间的作用.
- 每天服用NN1213导致肥胖大鼠在21天内显著,剂量依赖的体重减轻.
- 磁共振成像显示,体重减轻主要是由于脂肪质量下降.
结论:
- 在体重管理方面,NN1213表现出有利的药理动力学和药理动力学特征.
- 该化合物有效地降低了食欲,并促进了脂肪质量损失.
- 在肥胖和体重管理方面,NN1213是有前途的治疗候选药物.
相关概念视频
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Insulin: Biosynthesis, Chemistry, and Preparation
370
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
370
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.8K
Insulin Formulations: Types and Delivery
184
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
184
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K


